Teva Pharmaceutical Industries Ltd (XBUL:TEV)
лв 15.85 0 (0%) Market Cap: 17.96 Bil Enterprise Value: 48.53 Bil PE Ratio: 0 PB Ratio: 4.12 GF Score: 44/100

Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript

Jan 11, 2023 / 06:30PM GMT
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Teva this morning. From the company, we have the company's recently appointed CEO, Richard Francis; as well as CFO, Eli Kalif. Eli is going to make an initial presentation then we're going to move over to some Q&A with both Richard and with Eli. So with that, welcome and look forward to the presentation.

Eliyahu Sharon Kalif
Teva Pharmaceutical Industries Limited - Executive VP & CFO

Thank you, Chris. Welcome, everyone. And just before I start, I want to thank Chris and JPMorgan team to have us presenting here. It's really nice to come back and now after 3 years, really more exciting.

So today, we're going to review a few elements. We're going to talk about Teva today, and we're going to elaborate on how we are progressing with our current financial targets. We shift around the debt. And then also, I will elaborate more about what we communicated in the third -- in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot